AU2020269268A1 - CD123-binding polypeptides and uses thereof - Google Patents

CD123-binding polypeptides and uses thereof Download PDF

Info

Publication number
AU2020269268A1
AU2020269268A1 AU2020269268A AU2020269268A AU2020269268A1 AU 2020269268 A1 AU2020269268 A1 AU 2020269268A1 AU 2020269268 A AU2020269268 A AU 2020269268A AU 2020269268 A AU2020269268 A AU 2020269268A AU 2020269268 A1 AU2020269268 A1 AU 2020269268A1
Authority
AU
Australia
Prior art keywords
polypeptide
amino acid
seq
acid sequence
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020269268A
Other languages
English (en)
Inventor
William Crago
Brendan P. Eckelman
Andrew HOLLANDS
Kyle Jones
Milton MA
Chelsie Macedo
John C. Timmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inhibrx Biosciences Inc
Original Assignee
Inhibrx Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Biosciences Inc filed Critical Inhibrx Biosciences Inc
Publication of AU2020269268A1 publication Critical patent/AU2020269268A1/en
Assigned to INHIBRX BIOSCIENCES, INC. reassignment INHIBRX BIOSCIENCES, INC. Request for Assignment Assignors: Inhibrx, Inc.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020269268A 2019-05-04 2020-05-01 CD123-binding polypeptides and uses thereof Pending AU2020269268A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843407P 2019-05-04 2019-05-04
US62/843,407 2019-05-04
PCT/US2020/030968 WO2020227071A1 (en) 2019-05-04 2020-05-01 Cd123-binding polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
AU2020269268A1 true AU2020269268A1 (en) 2021-11-11

Family

ID=70740820

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020269268A Pending AU2020269268A1 (en) 2019-05-04 2020-05-01 CD123-binding polypeptides and uses thereof

Country Status (7)

Country Link
US (2) US11434297B2 (https=)
EP (1) EP3966242A1 (https=)
JP (2) JP2022532868A (https=)
CN (2) CN121021694A (https=)
AU (1) AU2020269268A1 (https=)
CA (1) CA3139061A1 (https=)
WO (1) WO2020227071A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7013753B2 (ja) * 2017-09-15 2022-02-01 株式会社三洋物産 遊技機
JP7013754B2 (ja) * 2017-09-15 2022-02-01 株式会社三洋物産 遊技機
JP6879413B2 (ja) * 2020-06-24 2021-06-02 株式会社三洋物産 遊技機
JP2020151570A (ja) * 2020-06-24 2020-09-24 株式会社三洋物産 遊技機
WO2022099175A1 (en) * 2020-11-09 2022-05-12 2Seventy Bio, Inc. Cd33 targeted immunotherapies
US20240076392A1 (en) * 2021-02-17 2024-03-07 Igm Biosciences, Inc. Anti-cd123 binding molecules and uses thereof
BR112023017099A2 (pt) * 2021-02-26 2023-11-21 Lava Therapeutics N V Anticorpos que se ligam a cd123 e a receptores de células t gama-delta
JP2021079225A (ja) * 2021-03-01 2021-05-27 株式会社三洋物産 遊技機
JP2021079226A (ja) * 2021-03-01 2021-05-27 株式会社三洋物産 遊技機
JP2021087836A (ja) * 2021-03-01 2021-06-10 株式会社三洋物産 遊技機
JP2021087833A (ja) * 2021-03-01 2021-06-10 株式会社三洋物産 遊技機
JP2024525727A (ja) 2021-07-14 2024-07-12 ２セブンティ バイオ インコーポレイテッド 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体
CA3255500A1 (en) 2022-04-08 2023-10-12 Regeneron Pharmaceuticals, Inc. MULTI-PART RECEIVERS AND SIGNALING COMPLEXES
JP7556433B2 (ja) * 2022-08-22 2024-09-26 株式会社三洋物産 遊技機
JP7556432B2 (ja) * 2022-08-22 2024-09-26 株式会社三洋物産 遊技機
JP7556434B2 (ja) * 2022-08-22 2024-09-26 株式会社三洋物産 遊技機
CN115724972B (zh) * 2022-09-06 2024-08-20 河北森朗生物科技有限公司 抗cd123的纳米抗体、嵌合抗原受体及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2541651C (en) 2003-10-22 2011-05-24 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
EP3925618A1 (en) 2013-07-29 2021-12-22 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
CN115160441A (zh) * 2013-09-26 2022-10-11 埃博灵克斯股份有限公司 双特异性纳米抗体
MX2017002205A (es) 2014-08-19 2017-08-21 Novartis Ag Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
EP3341410B1 (en) 2015-08-24 2021-06-02 Cellectis Chimeric antigen receptors with integrated controllable functions
UA122079C2 (uk) 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, що специфічно зв'язується з lrp5 і lrp6
EP3387014B1 (en) * 2015-12-11 2022-01-19 Leadartis, S.L. Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains
CN109952112B (zh) * 2016-09-21 2024-09-06 阿帕特夫研究和发展有限公司 Cd123结合蛋白和相关的组合物和方法
BR112019010061A2 (pt) * 2016-11-16 2019-08-13 Ablynx Nv polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
EP3548055A4 (en) * 2016-12-02 2020-08-19 University of Southern California SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE

Also Published As

Publication number Publication date
CN114040926A (zh) 2022-02-11
WO2020227071A1 (en) 2020-11-12
US20200347142A1 (en) 2020-11-05
JP2025060941A (ja) 2025-04-10
US11919963B2 (en) 2024-03-05
JP2022532868A (ja) 2022-07-20
US20230065306A1 (en) 2023-03-02
CA3139061A1 (en) 2020-11-12
CN121021694A (zh) 2025-11-28
JP7797614B2 (ja) 2026-01-13
US11434297B2 (en) 2022-09-06
CN114040926B (zh) 2025-07-29
EP3966242A1 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
US11919963B2 (en) CD123-binding polypeptides and uses thereof
JP7824999B2 (ja) ＣＬＥＣ１２ａ結合性ポリペプチド及びその使用
US12084502B2 (en) CD33-binding polypeptides and uses thereof
WO2020146221A1 (en) Polypeptides comprising modified il-2 polypeptides and uses thereof
CA3184618A1 (en) Polypeptides comprising modified il-2 polypeptides and uses thereof
EA046257B1 (ru) Clec12a-связывающие полипептиды и их применение
EA046221B1 (ru) Cd33-связывающие полипептиды и их применение